touchONCOLOGY meets with Dr Aditya Bardia at the Virtual 2020 ESMO Congress to discuss the recently presented data from the ASCENT trial, and the role sacituzumab govitecan may play in the treatment of previously-treated metastatic triple-negative breast cancer. The late-breaking abstract ‘ASCENT: A randomized phase 3 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)‘ (LBA17) was presented at the Virtual 2020 ESMO Congress, 12–21 September 2020.
- Why is triple-negative breast cancer so hard to treat, and what is the current standard of care for patients with metastatic disease? (0:15)
- Could you tell us a little about sacituzumab govitecan-hziy and its mechanism of action? (1:15)
- What were the aims and design of the ASCENT study? (2:48)
- What were the major efficacy and safety findings of the study? (3:29)
- How will these findings impact on clinical practice and what future studies are planned? (5:07)
Speaker Disclosures: Dr Aditya Bardia declares the following. Consultant/advisor for Biotheranostics, Daiichi Pharma/AstraZeneca, Genentech, Immunomedics, Lilly, Novartis, Pfizer, Puma Biotechnology, Merck, Philipps, Radius Health, Sanofi, Spectrum Pharmaceuticals, Foundation Medicine, and Taiho Pharmaceutical; research funding (to institution) from Biothernostics, Genentech/F. Hoffman-La Roche, Immunomedics, Innocrin Pharmaceuticals, Merck, Mersana Therapeutics, Novartis, Pfizer, Radius Health, and Sanofi.
Support: Interview and filming supported by Touch Medical Media Ltd. The ASCENT trial was sponsored by Immunomedics Inc.
Filmed in coverage of the Virtual 2020 ESMO Congress.
Share this Video
Related Videos In Breast Cancer
Javier Cortes, SABCS 2020 – Pembrolizumab in Triple-negative Breast Cancer
touchONCOLOGY joins Dr Javier Cortes at the San Antonio Breast Cancer Symposium (SABCS) 2020, to discuss the data being presented around the KEYNOTE-355 study and the potential of pembrolizumab as a treatment for triple-negative breast cancer (Clinical Trial Identifier: NCT02819518). The abstract ‘Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy […]
Janine Simons, SABCS 2020 – Radioactive Iodine Seed Localisation in the Axilla with the Sentinel Node Procedure: The RISAS Trial
We had the pleasure to talk to Janine Simons (Erasmus University Medical Center, Rotterdam, Netherlands) about the RISAS study and its findings (Clinical Trial Identifier: NCT02800317). The abstract ‘Radioactive Iodine Seed placement in the Axilla with Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer: Results of the prospective multicenter RISAS trial‘ (ABSTRACT NUMBER: […]
Leisha A Emens, ESMO 2020 – Overall Survival Analysis from IMpassion 130 in Triple-negative Breast Cancer
Prof. Leisha A Emens joins touchONCOLOGY to discuss the final overall survival analysis of the phase III IMpassion 130 study investigating atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Prof. Emens explores what we can learn from these findings, as well as the failure of IMpassion […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!